NR3C2 and heart failure: Data from the ARTS trial (Mineralocorticoid Receptor Antagonist Tolerability Study) support this safety profile, demonstrating a lower incidence of hyperkalemia with finerenone (4.5%) compared to spironolactone (11.1%) in patients with CKD and heart failure [64].